Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant gains Canadian rights to Xyrem
“Xyrem is a strategic fit for our existing marketing and sales organizations in Canada,” Valeant’s president and CEO, Timothy Tyson said. The agreement calls for Valeant to pay
“Xyrem is a strategic fit for our existing marketing and sales organizations in Canada,” Valeant’s president and CEO, Timothy Tyson said. The agreement calls for Valeant to pay
Of the patients who entered the study, 48% have survived more than six months. To date, 9.7% have demonstrated a clinical response to treatment, including one complete response
Voraxaze is an adjunctive therapy for patients experiencing, or at risk of, toxicity from methotrexate, a widely used anti-cancer agent. The company said that there will now be
Under German law, a domination and profit transfer agreement will enable UCB and Schwarz Pharma to operate as one fully integrated entity. Under the agreement, outside shareholders of
The phase I trial will test the safety and tolerability of single and multiple doses and first results are expected in the fourth quarter of 2007. The trial
Stimuvax is a type of therapeutic vaccine that targets a specific protein found in many tumors, including non-small cell lung cancer. It was developed by Biomira following Cancer
BioInvent believes the deal could accelerate its product development as retaining the North American rights gives the company an opportunity to increase participation and involvement in the antibody.
Intellect has said the antibodies are difficult to generate and so the acquisition could significantly accelerate its product development timeline. The antibodies are intended as a form of
Forest gains Cerexa’s antibiotic portfolio from the deal, which includes Cerexa’s lead compound ceftaroline acetate. The drug, which is in phase III trials, exhibits bactericidal activity against the
The completion of this milestone allows Ecopia to initiate the second portion of its clinical trial, the extension phase. During the dose-escalation portion of this trial, ECO-4601 was